Navigation Links
Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
Date:7/24/2012

vir against all major HIV subtypes resistant to current therapies, which may allow activity against tenofovir-resistant viruses (e.g., K65R), and against HBV.  CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects.  CMX157 has completed a Phase 1 clinical trial in healthy volunteers, demonstrating a favorable safety, tolerability and drug distribution profile. 

About Chimerix
Led by an experienced antiviral drug development team, Chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health.  The company's proprietary lipid technology has given rise to two clinical stage compounds, CMX001 and CMX157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. 

Chimerix's lead compound, CMX001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded DNA (dsDNA) viruses including cytomegalovirus (CMV), adenovirus, BK virus, herpes simplex virus and variola (smallpox).  CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV and is in Phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (HSCT) recipients.  To date, more than 750 patients have been dosed with CMX001 in controlled clinical trials and open-label treatment protocols.  Antiviral activity from completed and ongoing studies, coupled with the lack of myelotoxicity and nephrotoxicity that are associated with currently available therapies, indicate that CMX001 has the potential to improve outcomes for stem cell and solid organ transplant recipients.  Chimerix has completed an End of Phase 2 meeting with the FDA for CMX001 and is
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Chimerix Announces BK Virus Data In Late-Breaking Poster Session At The 24th International Congress Of The Transplantation Society
2. Chimerixs Broad Spectrum Antiviral Therapeutic, CMX001, Demonstrates Potential To Mitigate BK Virus Associated End-Organ Disease In Clinical Study
3. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
4. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
5. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
6. Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC
7. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
8. H. D. Smith Signs Three Year Prime Vendor Agreement with PharmacyGPO Buying Group
9. Bacterin International Signs Its Third National GPO Contract with Novation
10. MusclePharm Signs Pro Baseball Rookie Phenom Bryce Harper As Sponsored Athlete
11. Masimo Signs Pronto-7™ Distribution Deal with Henry Schein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 U.S. spending on ... complex diseases such as cancer, multiple sclerosis and rheumatoid ... the end of 2015, according to a forecast released ... (Logo: http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we ... and health plans to act so they can continue ...
(Date:5/21/2013)... , May 21, 2013 Reportlinker.com ... is available in its catalogue: ... Reimbursement Scenario for Medical Devices in the ...   Changing Regulatory and ... US Market   ...
(Date:5/21/2013)... 21, 2013  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... company focused on the development and commercialization ... acute and breakthrough pain, today announced top-line ... 3 study of its investigational sublingual Sufentanil ... the primary efficacy endpoint was achieved.  The ...
Breaking Medicine Technology:U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
(Date:5/21/2013)... 22, 2013 Swimsuit season is almost here. ... ® products has begun with a 35% discount. , Cellulite ... Many women get the dreaded cellulite even if they are ... skin where they have been stored as toxic lymph and ... easy fixes, a specific program that works to dissolve the ...
(Date:5/21/2013)... WASHINGTON (May 22, 2013)Today the George Washington ... Health Services (SPHHS) announced the launch of ... Immigrant/Refugee Health, a collaboration between SPHHS, the ... and other community partners. This university-community partnership ... disproportionately affect Latino communities through research, mutual ...
(Date:5/21/2013)... 21, 2013 DISCcert has served the ... to use 17 DISC applications at the July 25 ... progression. , The July 25 & 26th DISC certification ... ways of applying DISC. The time-tested, proven support materials ... user-friendly DISC training materials ; worksheets, handouts, ...
(Date:5/21/2013)... 21, 2013 ContinuCare Home Health, Inc. ... of Aging and Disability Services. After completing a four-day ... ContinuCare Home Health was found to have no ... part of the Department of Aging and Disability Services’ ... disability services, supports and opportunities that are easily ...
(Date:5/21/2013)... 21, 2013 Artisan Business Group ... Summit: Dealmakers Conference in Long Beach, California on ... on exploring alternative finance through EB-5 immigrant investors ... legal and economic information, and updates to project ... within the EB-5 industry. , "Our goal ...
Breaking Medicine News(10 mins):Health News:Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale" 2Health News:GW launches center to address health disparities in the Latino immigrant community 2Health News:GW launches center to address health disparities in the Latino immigrant community 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2
... regional pain syndrome is a neurological disorder caused by continuous ... sense pain. // ,This syndrome includes all the post-traumatic ... injury has healed. But the causes of the symptoms of ... the fact that there are very few objective findings, diagnosis ...
... British Prime Minister Tony Blair today formally inducted 11 private ... further step towards increasing competition in the health sector. //Mr ... members at a summit held at Downing Street to mark ... signed a document pledging to work as partners towards 'future ...
... is the key to weight loss a new study says ... //, ,This study comes from the Canadian Institute for ... work can help make or break our battle against the ... CIHI's Canadian Population Health Initiative, "We see that the majority ...
... pollution in the air now that if it weren't for ... -Robert Orben // ,The order of the ... Clemenceau to be sent back to France, represents the overall ... The order has been issued following dismissal of the proposed ...
... profound impact on either couple, men seem to be more ... Christakis and his research team from Harvard Medical School. ... spouse on the risk of illness in the other partner ... elderly couples. ,They found that when a spouse ...
... at the Washington Hospital Center studied the use of ... blocked arteries. // ,These blocked arteries are ... as it leads to devastating complications such as amputation. ... high blood pressure are at high risk for losing ...
Cached Medicine News:Health News:Location largely affects weight 2Health News:The Return Of The Clemenceau: Happy India 2Health News:Laser Used To Clear Blocked Arteries Preventing Amputation, 2
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Provides basic reduction capabilities for angulation, rotation and length. Ball joint design offers fracture reduction in all planes....
... The Holding Clamps have a slender design ... sequential tensioning of Kirschner wires. The Connecting ... Fiber Rods and/or Connecting Bar. Uses 3.0 ... tip Kirschner wires eliminate need to predrill ...
The Elbow Fixator has ontrolled movement about the axis of rotation of the elbow joint. It is minimally invasive and rapidly applied....
Medicine Products: